摘要
目的 讨论在急性缺血性脑卒中伴发下肢深静脉血栓患者中使用低分子肝素钙治疗的效果,并评估其安全性。方法 选取50例急性缺血性脑卒中伴发下肢深静脉血栓患者,按随机数字表法分为对照组与治疗组,每组25例。对照组给予脑卒中常规治疗,治疗组给予脑卒中常规治疗联合低分子肝素钙治疗。比较两组临床疗效、临床预后[美国国立卫生研究院卒中量表(NIHSS)评分]、静脉血栓栓塞(VTE)风险[无手术患者静脉血栓栓塞风险评分表(Padua)评分]、不良反应(血小板减少、注射部位皮肤变化、肝肾功能异常、出血)发生率。结果 治疗组总有效率为80%,对照组总有效率为52%,治疗组高于对照组,差异有统计学意义(P<0.05)。治疗后,治疗组NIHSS评分(7.08±1.29)分低于对照组的(11.24±1.20)分,差异具有统计学意义(P<0.05)。治疗后,治疗组Padua评分(2.28±1.02)分低于对照组的(4.40±1.35)分,差异具有统计学意义(P<0.05)。治疗组不良反应发生率为28%(7/25),对照组不良反应发生率为32%(8/25),两组比较无统计学意义(P>0.05)。结论 低分子肝素钙可以促进急性缺血性脑卒中伴发下肢深静脉血栓患者肢体功能恢复,减少不良反应发生,在急性缺血性脑卒中伴发下肢深静脉血栓的治疗中取得理想效果。
Objective To explore the effect of low molecular weight heparin calcium for acute ischemic stroke with lower extremity deep venous thrombosis and evaluate its safety.Methods 50 patients with acute ischemic stroke and lower extremity deep venous thrombosis were divided into a control group and a treatment group according to random numerical table,with 25 cases in each group.The control group was given conventional therapy,and the treatment group was given conventional therapy combined with low molecular weight heparin calcium therapy.Both groups were compared in terms of clinical efficacy,clinical prognosis[National Institutes of Health Stroke Scale(NIHSS)score],the risk of venous thromboembolism(VTE)(Padua score),and the incidence of adverse reactions(thrombocytopenia,skin changes at the injection site,abnormal liver and kidney function,and bleeding).Results The total effective rate of the treatment group was 80%,while the total effective rate of the control group was 52%;the treatment group was higher than the control group,and the difference was statistically significant(P<0.05).After treatment,the NIHSS score of the treatment group was(7.08±1.29)points,which was lower than(11.24±1.20)points of the control group,and the difference was statistically significant(P<0.05).After treatment,Padua score of the treatment group was(2.28±1.02)points,which was lower than(4.40±1.35)points of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 28%(7/25)in the treatment group and 32%(8/25)in the control group,and there was no statistical significance between the two groups(P>0.05).Conclusion Low molecular weight heparin calcium can promote the recovery of limb function and reduce the occurrence of adverse reactions in patients with acute ischemic stroke complicated with lower extremity deep venous thrombosis,and achieve ideal results in the treatment of acute ischemic stroke complicated with lower extremity deep venous thrombosis.
作者
席富强
常昕
董向力
XI Fu-qiang;CHANG Xin;DONG Xiang-li(First Department of Neurology,First Affiliated Hospital of Baotou Medical College,Baotou 014010,China)
出处
《中国实用医药》
2024年第11期100-103,共4页
China Practical Medicine
基金
包头医学院中青年科技骨干支持计划(项目编号:BYJJ-QNGG 2022051)项目名称:低分子肝素治疗急性缺血性脑卒中伴发下肢深静脉血栓的疗效和安全性评估。
关键词
急性缺血性脑卒中
下肢深静脉血栓
低分子肝素钙
Acute ischemic stroke
Lower extremity deep venous thrombosis
Low molecular weight heparin calcium
